Physician profile
John B Pope
NPI 1669614863
$40,029.09
in general payments reported to CMS, 2019-2025
13 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,945 · 2020: $5,444 · 2021: $365 · 2022: $11K · 2023: $12K · 2024: $5,916 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $2,131 · Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,450.00 |
| Travel and Lodging | $2,131.30 |
| Food and Beverage | $694.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $26,161.91 | 2019-2025 | Tapestry |
| Medical Device Business Services, INC. | $12,667.80 | 2019-2024 | Attune |
| Depuy Synthes Sales INC. | $554.54 | 2019-2024 | Attune |
| Stryker Corporation | $180.31 | 2019-2025 | Mako |
| Smith+Nephew, INC. | $149.62 | 2021-2023 | Pico |
| Avanos Medical | $93.19 | 2020 | |
| Ethicon US, LLC | $63.23 | 2024-2025 | Dermabond, Ethicon, Stratafix |
| Horizon Therapeutics Plc | $59.63 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $28.59 | 2025 | |
| Dynasplint Systems INC. | $25.64 | 2022 | |
| Convatec INC. | $18.39 | 2019 | |
| Next Science LLC | $13.88 | 2023 | Surgx, Blastx, Xperience |
| Heraeus Medical, LLC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.